Targeted Medical Pharma Inc · OTC:TRGM
Targeted Medical Pharma — Investor Presentation (September 2013)
37 slides from Targeted Medical Pharma's investor presentation, Sep 9, 2013
Slide 1: Targeted Medical Pharma, Inc. Innovators in Pharmaceutical Technology
Targeted Medical Pharma, Inc. Innovators in Pharmaceutical Technology September 2013
Slide 2: Safe Harbor Statement
Safe Harbor Statement This document does not constitute or form part of an invitation or recommendation to subscribe for or purchase any securities of Targeted Medical Pharma, Inc . (“Targeted Medical Pharma”, “TMP” or “the Company”) . This document was prepared exclusively for the benefit and inter
Slide 3: A Biotech Leader in the Rx-Only, Medical Foods Market
A Biotech Leader in the Rx - Only, Medical Foods Market TARGETED MEDICAL PHARMA (OTCQB:TRGM) 3 3 Core Products Treating Major Disease Markets Pharmaceutical Platforms Applicable to Multiple Diseases Growing Revenue Reimbursed Products, Contract Receivables Low - Cost Product Development No FDA Pre -
Slide 4: Company Snapshot
Company Snapshot TARGETED MEDICAL PHARMA (OTCQB:TRGM) Biotechnology company founded in 1999 (OTCQB : TRGM) Low - cost development platform Ten FDA - regulated, Rx - only products on the market Medical technologies applicable to multiple diseases Safe option for treatment of common medical
Slide 5: About Rx-Only Medical Foods
Medical foods are FDA - regulated medications intended for the dietary management of a disease that has distinctive nutritional needs that cannot be met by normal diet alone as defined in the Food and Drug Administration's 1988 Orphan Drug Act Amendments . About Rx - Only Medical Foods TARGETED MEDI
Slide 6: Targeted Cellular Technology: Five-component System for Amino Acid Uptake
Five - component System for Efficient Uptake and Utilization of Amino Acids Targeted Cellular Technology® TARGETED MEDICAL PHARMA (OTCQB:TRGM) 6 Reduced Attenuation Improved Efficacy Milligram Quantities Amino Acids Are the Precursors to Neurotransmitters >> 5 HTP Choline Arginine Tyrosine GABA Hist
Slide 7: Liquid Oral Administration System "Swish and Swallow"
Liquid Oral Administration System “Swish and Swallow” TARGETED MEDICAL PHARMA (OTCQB:TRGM) 7 Rapid absorption by mouth with a venous system that by passes portal drainage Absorbed within seconds due to high oral vascularization
Slide 8: Product Rollout and Pipeline
Product Indication Phase 1 Phase 2 Phase 3 Actively Promoted (% of monthly doses)** Theramine Pain Complete 42% Sentra PM / GABAdone Sleep Disorders Complete 24% Trepadone Osteoarthritis Complete 12% Sentra AM Cognitive Disorders, Fatigue, Vision Complete 11% AppTrim and AppTrim-D Metabolic Disorder
Slide 9: Consistent Biotechnology Development Track Record
TARGETED MEDICAL PHARMA (OTCQB:TRGM) Consistent Biotechnology Development Track Record 9 Obesity and Metabolic Syndrome with Apptrim ® Hypertension with Hypertensa ® Sleep disorders with Sentra PM® and GABAdone ® Cognitive dysfunction with Sentra AM ® Fibromyalgia with Theramine®, Sentra PM® and Sen
Slide 10: Medical Foods: Meeting Physician & Patient Demand
SOLUTIONS • Nutritional management of disease • Safe, effective treatments • Reduce dosage of opiates • Improved adherence Medical Foods: Meeting Physician & Patient Demand TARGETED MEDICAL PHARMA (OTCQB:TRGM) 10 NEEDS • Improve patient o utcomes • Reduce negative s ide e ffects • Lower costs of car
Slide 11: Low-Cost, Shorter Time to Market
Low - Cost, Shorter Time to Market TARGETED MEDICAL PHARMA (OTCQB:TRGM) 11 Rx Medical Foods Have a Shorter Time to Market due to GRAS/GRAE status Development and Testing (1 to 2 yrs) Database Registration (3 to 6 mos ) Revenue and Post - Marketing MedWatch (Milestone) IND Submission (Milestone) Data
Slide 12: Two Platform Technologies
Two Platform Technologies TARGETED MEDICAL PHARMA (OTCQB:TRGM) 12 Targeted Amino Acid Technology (TAT) Targeted Cellular Technology (TCT)
Slide 13: Inflammation Reduction with Theramine
Inflammation Reduction with Theramine® TARGETED MEDICAL PHARMA (OTCQB:TRGM) 13 184.5 - 16.7 - 78.6 -100 -50 0 50 100 150 200 Percent (%) Change in hsCRP from Baseline at 28 Days Naproxen Theramine Both p<0.01 n=126 Source: Shell , et al.,“A Double - Blind Controlled Trial of a Single Dose Naproxen a
Slide 14: Clinical Trial: Theramine with Ibuprofen (Theraprofen)
Clinical Trial: Theramine® with Ibuprofen (Theraprofen®) TARGETED MEDICAL PHARMA (OTCQB:TRGM) 14 0.09 - 6.15 - 9.08 -10 -8 -6 -4 -2 0 2 Ibuprofen Theramine Combination Change in VAS from Day 1 to day 28 Roland Morris Score After 28 Days n=122 p<( 0.01 ) - 6.2 - 9.1 0.1 Source: Shell , et al., “A Dou
Slide 15: Clinical Trial: Theramine with Ibuprofen (Theraprofen)
Clinical Trial: Theramine® with Ibuprofen (Theraprofen®) TARGETED MEDICAL PHARMA (OTCQB:TRGM) 15 Source: Shell , et al., “A Double - Blind Controlled Trial of a Single Dose Ibuprofen and an Amino Acid Medical Food Theramine for the Treatment of Low Back Pain; Publication pending, 2010. Patients with
Slide 16: Pain Reduction with Theramine
Pain Reduction with Theramine® TARGETED MEDICAL PHARMA (OTCQB:TRGM) 16 Source: Shell , et al.,“A Double - Blind Controlled Trial of a Single Dose Naproxen and an Amino Acid Medical Food Theramine for the Treatment of Low Back Pain”; American Journal of Therapeutics; 2012 108 - 114 2.95 - 44 - 65 -70
Slide 17: Disability Reduction with Theramine and Naproxen
Disability Reduction with Theramine ® and Naproxen ( Theraproxen ®) TARGETED MEDICAL PHARMA (OTCQB:TRGM) 17 Source: Shell , et al.,“A Double - Blind Controlled Trial of a Single Dose Naproxen and an Amino Acid Medical Food Theramine for the Treatment of Low Back Pain”; American Journal of Therapeuti
Slide 18: Pharmacoeconomic Analysis of Theramine
Pharmacoeconomic Analysis of Theramine TARGETED MEDICAL PHARMA (OTCQB:TRGM) Theramine NSAID Product 633,600,000$ 36,000,000$ GI Bleed Treatment - 225,000,000 Protective Medications - 432,000,000 Laboratory Testing 1,000,000 75,000,000 Negative GI Workup - 144,000,000 Total 634,600,000$ 912,000,000$
Slide 19: Clinical Trial: Sentra PM and Trazodone
Clinical Trial: Sentra PM® and Trazodone (Trazamine®) TARGETED MEDICAL PHARMA (OTCQB:TRGM) 19 1 Pittsburgh Sleep Quality Index Source: Shell , et al., “Sentra PM and Trazodone for the management of Sleep Disorders” Journal of Central Nervous System Disease; 2012:4 1.0 2.0 3.9** 6.5** 0 1 2 3 4 5 6 7
Slide 20: Clinical Trial: Sentra PM and Trazodone
Clinical Trial: Sentra PM® and Trazodone (Trazamine®) TARGETED MEDICAL PHARMA (OTCQB:TRGM) 20 Source: Shell , et al., “Sentra PM and Trazodone for the management of Sleep Disorders” Journal of Central Nervous System Disease; 2012:4 Change in Visual Analog Scale (VAS) Negative change indicates reduce
Slide 21: Pipeline: Initial Data Indicating ESS-1818 Increases Red Blood Cell Production
1 Effect on one patient in pre - clinical trials. Pre - clinical trials resulted in an 80% response rate. Pipeline: Initial Data Indicating ESS - 1818 Increases Red Blood Cell Production TARGETED MEDICAL PHARMA (OTCQB:TRGM) 21 Source: Initial data from an open label study of an oral amino acid - bas
Slide 22: Autism Product
Autism Product TARGETED MEDICAL PHARMA (OTCQB:TRGM) 22 0 1 2 3 4 5 1 2 3 4 5 6 7 8 Day Initiation of Treatment Number of Events Involving Anger, Frustration, and Self - Directed Aggressive Behavior Nutritional Deficiency Initial Data Development Status Distribution Channels Anticipated Lau
Slide 23: Appetite Suppression Product
Appetite Suppression Product TARGETED MEDICAL PHARMA (OTCQB:TRGM) 23 Nutritional Deficiency Initial Data Development Status Distribution Channels Anticipated Launch Date Appetite Suppression Early Satiety Carbohydrate Craving Increase in Fat Metabolism 152 154 156 158 160 162 164 1
Slide 24: Intellectual Property Highlights
Intellectual Property Highlights TARGETED MEDICAL PHARMA (OTCQB:TRGM) 1 Targeted Cellular Technology® is a five - component system the stimulates the uptake and utilization of amino acids. It enables efficacy from microgram quantities of amino acids. *First Known Oral Stimulation of Stem Cells 24 Se
Slide 25: Financials and Team
Innovators in Pharmaceutical Technology Financials and Team
Slide 26: Financial Snapshot
Financial Snapshot TARGETED MEDICAL PHARMA (OTCQB:TRGM) 26 Summary 6 mos ended June 30, 2013 6 mos ended June 30, 2012 QoQ Change $ QoQ Change % Revenue $4.7 million $2.8 million $1.9 million 67% Operating Expenses $5.4 million $4.8 million $0.6 million 12% Shares Outstanding 23.4 million 21.9 milli
Slide 27: Financial Snapshot
Financial Snapshot TARGETED MEDICAL PHARMA (OTCQB:TRGM) 27 • OTCQB:TRGM • Trading started October 2012 • Stock Price as of August 30, 2013: $1.04 • 3 Month Avg. Volume: 9,600 shares per day • Shares owned by insiders: Approx. 60% • DTC , FAST, DWAC implemented $- $1,000 $2,000 $3,000 $4,000 $5,000 1
Slide 28: Off-Balance Sheet Asset: Contract Receivables
Shipments : Contract Receivables Collections : Recognized Revenue Contract Receivables are amounts due but not yet recognized as revenue Monthly collections are approximately 1.5% to 2.0% Collected amounts impact bottom - line operating revenue almost directly Contract receivables are constantly rej
Slide 29: Improving the Reimbursement Mix
Improving the Reimbursement Mix TARGETED MEDICAL PHARMA (OTCQB:TRGM) 29 75% 20% 5% 60% 35% 5% 55% 30% 5% 10% 35% 35% 15% 15% 2011 2012 2013 2014 Diversification of Payers Revenue Stability Workers Compensation Private Insurance Medicare Part D DOD / VA
Slide 30: Reimbursement Channels
Reimbursement Channels TARGETED MEDICAL PHARMA (OTCQB:TRGM) 30 Medicare Advantage / Secondary DOD / VA Medicaid Tricare Cigna BlueCross/Blue Shield United Healthcare Aetna Health Net Rx Solutions Medco Caremark Catamaran (Walgreens) MedImpact Express Scripts Workers ’ Compe
Slide 31: Geographic Presence and Potential
Geographic Presence and Potential TARGETED MEDICAL PHARMA (OTCQB:TRGM) 31 With limited sales resources, TRGM has sold product into only a fraction of its potential market. The core purpose of funding is sales expansion.
Slide 32: Near-Term Catalysts & Goals
Near - Term Catalysts & Goals TARGETED MEDICAL PHARMA (OTCQB:TRGM) 32 Grow sales to physicians with well - insured (PPO) patients • A National Sales Manager was hired in March • A contract was signed to accelerate cash collections • We are contemplating the acquisition of a distributor network Begin
Slide 33: Key Management
Key Management TARGETED MEDICAL PHARMA (OTCQB:TRGM) 3 3 David Silver, M.D. President and Chief Operating Officer • University of California Los Angeles - Associate Professor • Cedars - Sinai Medical Center – Clinical Chief of Rheumatology and Dir. of Chronic Pain Rehabilitation Program • Osteoporosi
Slide 34: Board of Directors
Board of Directors TARGETED MEDICAL PHARMA (OTCQB:TRGM) 34 INDEPENDENT DIRECTORS Maurice J. DeWald Chairman of the Board and of the Compensation Committee KPMG - Regional Managing Partner Serves on the board of director of several healthcare companies Arthur R. Nemiroff Chairman of the Audit Committ
Slide 35: Business Team
Business Team TARGETED MEDICAL PHARMA (OTCQB:TRGM) 35 Legal Counsel Equities Accounting Investor Relations and Public Relations FDA HEALTHCARE HEALTHCARE SECURITIES AUDITORS TAX ACCOUNTANTS INVESTOR RELATIONS PUBLIC RELATIONS PondelWilkinson MARKET MAKER TRANSFER AGENT
Slide 36: Investment Considerations
Investment Considerations PRODUCTS HAVE LOW SIDE - EFFECT PROFILE TARGETED MEDICAL PHARMA (OTCQB:TRGM) 36 HIGH DEMAND PRODUCTS ADDRESSING LARGE MARKETS DIVERSIFIED, GROWING SALES GROWING ADOPTION OF MEDICAL FOODS BROAD - REACHING PATENTS AND ROBUST PIPELINE PROVEN SAFETY AND EFFICACY THROUGH CLINICA
Slide 37: Contact
Contact 2980 Beverly Glen Circle, Suite 301 Los Angeles, CA 90077 Telephone: 310 - 474 - 9809 Fax: 310 - 531 - 7089 investors@tmedpharma.com Brand site: www.ptlcentral.com Company site: www.tmedpharma.com
Targeted Medical Pharma — Investor Presentation (September 2013) on 6ix